References
- MEDEV - Medicines evaluation committee; 2018. Available from: www.medev-com.eu
- AIM. - Association internationale de mutualite; 2018. Available from: https://www.aim-mutual.org/
- ESIP - European social insurance platform. Available from: www.esip.eu
- Vaisman E. ADOPTION OF THE ENVI REPORT ON HTA - ESIP welcomes a balanced approach to HTA at EU level; 2018. Available from: https://www.esip.eu/new/details/2/55-Adoption%20of%20the%20ENVI%20report%20on%20HTA
- European Parliament. Draft Report on the proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051 – C8-0024/2018/0018(COD)), Committee on the Environment, Public Heath and Food Safety; 2018. Available from: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&reference=PE-622.011&format=PDF&language=EN&secondRef=01
- EUPATI. Economic evaluation in HTA; 2016. Available from: https://www.eupati.eu/health-technology-assessment/economic-evaluation-in-hta/
- Banta D, Oortwijn W. Introduction: health technology assessment and the European Union. Int J Technol Assess Health Care. 2000;16(2):299–302.
- Council of the European Union. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States; 2016. Available from: http://www.consilium.europa.eu/en/press/press-releases/2016/06/17-epsco-conclusions-balance-pharmaceutical-system/
- Consolidated version of the Treaty on the Functioning of the European Union (TFEU) Official Journal of the European Union; 2008. Available from: https://eur-lex.europa.eu/resource.html?uri=cellar:41f89a28-1fc6-4c92-b1c8-03327d1b1ecc.0007.02/DOC_1&format=PDF
- European Commission, DG GROWTH; 2018. Available from: https://ec.europa.eu/growth/sectors/healthcare/competitiveness/products-pricing-reimbursement/transparency-directive_en
- Banta D, Kristensen FB, Jonsson E. A history of health technology assessment at the European level. Int J Technol Assess Health Care. 2009;25(Suppl 1):68–73.
- Oortwijn W, Broos P, Vondeling H, et al. Mapping of health technology assessment in selected countries. Int J Technol Assess Health Care. 2013;29(4):424–434.
- EUnetHTA. History; 2018. Available from: https://www.eunethta.eu/about-eunethta/history-of-eunethta/
- EUnetHTA Mission, vision and values; 2018. Available from: https://www.eunethta.eu/about-eunethta/mission-vision-and-values/
- KCE REPORT 283. HORIZON SCANNING FOR PHARMACEUTICALS: PROPOSAL FOR THE BENELUXA COLLABORATION. Available from: http://www.beneluxa.org/sites/beneluxa.org/files/2017-07/Horizon%20scanning_ScientificReport_full.pdf
- Espín J, Rovira J, Calleja A et al. European Observatory. Policy Brief 21. 2016. How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe? Available from: https://www.eu2017.mt/Documents/Programmes/PB21.pdf
- Press Release. Ireland to open negotiations with Belgium, the Netherlands, Luxembourg and Austria on drug pricing and supply – minister Harris. Available from: http://health.gov.ie/blog/press-release/ireland-to-open-negotiations-with-belgium-the-netherlands-luxembourg-and-austria-on-drug-pricing-and-supply-minister-harris/.
- Henrard S, Arickx F. Negotiating prices of drugs for rare diseases. Bull World Health Organ. 2016;94(10):779–781.
- European Commission. Health technology assessment network; 2018. Available from: https://ec.europa.eu/health/technology_assessment/policy/network_en.
- EU Health Technology Assessment Network. Strategy for EU cooperation on health technology assessment; 2014. Available from: https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/2014_strategy_eucooperation_hta_en.pdf
- Council of the European Union. Council conclusions on encouraging member states-driven voluntary cooperation between health systems; 2017. Available from: http://data.consilium.europa.eu/doc/document/ST-9978-2017-REV-1/en/pdf
- European Commission. Better Regulation: why and how. 2016. Available from: https://ec.europa.eu/info/law/law-making-process/better-regulation-why-and-how_en
- European Commission, Public Health, Health Technology Assessment. Public Consultation on Strengthening EU Cooperation on Health Technology Assessment (HTA); 2016. Available from: https://ec.europa.eu/health/technology_assessment/consultations/cooperation_hta_en
- EUnetHTA HTA Core Model ®; 2018. Available from: https://www.eunethta.eu/hta-core-model/
- European Commission. Strengthening of the EU cooperation on Health Technology Assessment (HTA), Inception Impact Assessment; 2016. Available from: http://ec.europa.eu/smart-regulation/roadmaps/docs/2016_sante_144_health_technology_assessments_en.pdf
- European Commission, DG SANTE. Proposal for a regulation of the European parliament and of the council on health technology assessment and amending directive 2011/24/EU (2018/0018(COD); 2018. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52018PC0051&from=EN
- Mayor S. Differences in availability of cancer drugs across Europe. Lancet Oncol. 2016;17(9):1196.
- Cherny N, Sullivan R, Torode J, et al. ESMO European consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27(8):1423–1443.
- EURODIS. Breaking the access deadlock to leave no one behind. a contribution by EURORDIS and its members on possibilities for patients’ full and equitable access to rare disease therapies in Europe; 2018. Available from: http://download2.eurordis.org.s3.amazonaws.com/positionpapers/eurordis_access_position_paper_final_4122017.pdf
- Detiček A, Locatelli I, Kos M. Patient access to medicines for rare diseases in European countries. Value Health. 2018;21(5):553–560.
- Kwon H-Y, Kim H, Godman B. Availability and affordability of drugs with a conditional approval by the european medicines agency; comparison of Korea with other countries and the implications. Front Pharmacol. 2018;9:938.
- Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
- Kostic M, Djakovic L, Sujic R, et al. Inflammatory bowel diseases (Crohn s disease and ulcerative colitis): cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017;15(1):85–93.
- Paris V, Belloni A Value in pharmaceutical pricing. Available from: http://www.oecd-ilibrary.org/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en
- Godman B, Oortwijn W, de Waure C et al. Links between Pharmaceutical R&D Models and Access to Affordable Medicines. A Study for the ENVI COMMITTEE. Available from: http://www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_STU(2016)587321_EN.pdf
- WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015. Available from: http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1
- Kahveci R, Oortwijn W, Godman B, et al. Role of health technology assessment in pharmaceutical market access in developed countries in pharmaceutical market access in developed countries edited by Koçkaya G and Wertheimer A. 2018. Available from: http://books.seedmedicalpublishers.com/index.php/seed/catalog/view/Pharmaceutical_MA_developed/PDF/747.ch15.
- Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
- Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
- Matusewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–758.
- Ferrario A, Arāja D, Bochenek T, et al. The implementation of managed entry agreements in central and eastern europe: findings and implications. PharmacoEconomics. 2017;35(12):1271–1285.
- Ferrario A, Kanavos P Managed entry agreements for pharmaceuticals: the European experience. EMiNet, Brussels, Belgium; 2013. Available from: http://eprints.lse.ac.uk/50513/
- Carlson JJ, Chen S, Garrison LP Jr. Performance-Based Risk-Sharing Arrangements: an Updated International Review. PharmacoEconomics. 2017;35(10):1063–1072.
- Have AT, Oortwijn W, Broos P, et al. European cooperation on health technology assessment - economic and governance analysis of the establishment of a permanent secretariat. 2013. Available from: https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/study_ecorys_european_cooperation_hta_en.pdf
- Banta D, Oortwijn W. Health technology assessment and health care in the European Union. Int J Technol Assess Health Care. 2000;16(2):626–635.
- Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017;359:j4543.
- Godman B, Wild C, Haycox A. Patent expiry and costs for anti-cancer medicines for clinical use.GABI 2017;6(2):1–2.
- Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.
- Haycox A. Why cancer? PharmacoEconomics. 2016;34(7):625–627.
- Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European medicines agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530.
- WHO. Informal advisory group on the availability and affordability of cancer medicines; 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/272961/WHO-EMP-IAU-2018.04-eng.pdf?ua=1.
- Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
- Hill A, Redd C, Gotham D, et al. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ open. 2017;7(1):e011965.
- Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996–1000.
- Editorial. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–4442.
- Ghinea H, Kerridge I, Lipworth W If we don’t talk about value, cancer drugs will become terminal for health systems. Available from: http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072
- IMS Institute for Healthcare Informatics. Global oncology trend report. a review of 2015 and outlook to 2020; 2016 Jun. Available from: https://www.scribd.com/document/323179495/IMSH-Institute-Global-Oncology-Trend-2015-2020-Report
- Garner S, Rintoul A, Hill SR. Value-based pricing: L’Enfant terrible? PharmacoEconomics. 2018;36(1):5–6.
- WHO fair pricing. Informal advisory group meeting; 2016 November 22-24; Geneva: WHO Headquarters. Available from: https://www.who.int/medicines/access/fair_pricing/report_fair_pricing-forumIGmeeting.pdf?ua=1
- Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8(4):357–371.
- Vogler S, Kilpatrick K, Babar ZU. Analysis of medicine prices in New Zealand and 16 European countries. Value Health. 2015;18(4):484–492.
- Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39–47.
- Leopold C, Vogler S, Mantel-Teeuwisse AK, et al. Differences in external price referencing in Europe: a descriptive overview. Health Policy. 2012;104(1):50–60.
- Vogler S, Zimmermann N, Babar ZU. Price comparison of high-cost originator medicines in European countries. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):221–230.
- Kalo Z, Gheorghe A, Huic M, et al. HTA implementation roadmap in central and Eastern European countries. Health Econ. 2016;25(Suppl 1):179–192.
- Farkas AM, Mariz S, Stoyanova-Beninska V, et al. Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe. Front Med (Lausanne). 2017;4:53.
- Narayanan G, Cossu G, Galli MC, et al. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European union. Hum Gene Ther Clin Dev. 2014;25(1):1–6.
- Hanna E, Rémuzat C, Auquier P, et al. Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy. 2017;5(1):1265293.
- Hampson G, Towse A, Pearson SD, et al. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018;7(1):15–28.
- Marsden G, Towse A, Pearson SD, et al. Gene therapy: understanding the science, assessing the evidence, and paying for value. Available from: https://www.ohe.org/news/new-publication-gene-therapy-understanding-science-assessing-evidence-and-paying-value
- Gomes RM, Guerra Junior AA, Lemos LL, et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Rev Clin Pharmacol. 2016;9(7):991–999.
- Garcia-Doval I, Cohen AD, Cazzaniga S, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries. J Am Acad Dermatol. 2017;76(2):299–308.e16.
- Raaschou P, Simard JF, Asker Hagelberg C, et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016;352:i262.
- Henshall C, Sampson L, Eichler H-G, et al. Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: what are they looking for, and how and why does this differ from what regulators require? Ther Innov Regul Sci. 2013;48(3):341–346.
- Prasad V, Kim C, Burotto M, et al. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175(8):1389–1398.
- Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
- Kleijnen S, Lipska I, Leonardo Alves T, et al. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Ann Oncol. 2016;27(9):1768–1775.
- INTEGRATE-HTA report summary. final report summary - INTEGRATE-HTA (Integrated health technology assessment for evaluating complex technologies); 2017. Available from: https://cordis.europa.eu/project/rcn/105703/reporting/en
- EUnetHTA. An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report; 2018. Available from: https://www.eunethta.eu/an-analysis-of-hta-and-reimbursement-procedures-in-eunethta-partner-countries-final-report/
- MedTecHTA. Methods for health technology assessment of medical devices: a european perspective; 2018. Available from: http://www.medtechta.eu/wps/wcm/connect/Site/MedtecHTA/Home
- European Parliament. REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL; 2004. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf
- Eriksson I, Wettermark B, Persson M, et al. The early awareness and alert system in Sweden: history and current status. Front Pharmacol. 2017;8:674.
- Godman B, Joppi R, Bennie M, et al. Chapter 20, Managed introduction of new drugs. Elseviers M, Wettermark B, Almarsdottir AB, Andersen M, Benko R, Bennie M, et al. editors. drug utilization research: methods and applications. Chichester: John Wiley & Sons; 2016. p. 210–221. ISBN: 978-1-118-94978-8
- Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol. 2014;5:109.
- Frisk P, Aggefors K, Cars T, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018;74(7):971–978.
- Mueller T, Alvarez-Madrazo S, Robertson C, et al. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019;85(2):422–431.
- Vella Bonanno P, Ermisch M, Godman B, et al. Adaptive pathways: possible next steps for payers in preparation for their potential implementation. Front Pharmacol. 2017;8:497.
- van de Wetering EJ, van Exel J, Brouwer WB. The challenge of conditional reimbursement: stopping reimbursement can be more difficult than not starting in the first place! Value Health. 2017;20(1):118–125.
- Puthumana J, Wallach JD, Ross JS. Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation. Jama. 2018;320(3):301–303.
- Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47.
- Annemans L The use of real world data throughout an innovative medicine’s lifecycle; 2017. Available from: https://www.inami.fgov.be/SiteCollectionDocuments/real_world_data.docx
- IMI GetReal. New methods for RWE collection and synthesis; 2018. Available from: http://www.imi-getreal.eu/
- Official Journal of the European Union. DIRECTIVE 2011/62/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL; 2011 Jun. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2011_62/dir_2011_62_en.pdf
- European Medicines Agency; 2018. Available from: http://www.ema.europa.eu/ema/.
- Heads of Medicines Agencies; 2018. Available from: http://www.hma.eu/.
- Baldwin R, Cave M, Lodge M. Understanding regulation – theory, strategy and practice. 2nd ed. Oxford: Oxford University Press; 2011. Available from: https://www.researchgate.net/publication/227468181_Understanding_Regulation_Theory_Strategy_and_Practice
- Packer C, Simpson S, de Almeida RT. Euroscan international network member agencies: their structure, processes, and outputs. Int J Technol Assess Health Care. 2015;31(1–2):78–85.
- Heon-Klin V. European Reference networks for rare diseases: what is the conceptual framework? Orphanet J Rare Dis. 2017;12(1):137.